Japan’s Takeda sells four diabetes products to Teijin Pharma for $1.25 billion | ReutersTOKYO (Reuters) –
Takeda Pharmaceutical Co said on Friday it agreed to sell four diabetes products in Japan to Teijin Pharma Ltd for 133 billion yen ($1.25 billion).Takeda will sell the Japanese marketing rights of drugs Nesina, Liovel, Inisync and Zafatek to Teijin Pharma subject to regulator approval, the company said in a release. The drugs generated 30.8 billion yen in sales in fiscal 2019, Takeda said. The sale is the latest in a series of deals that Takeda has undertaken to reduce debt and refocus its business after its purchase of Shire Ltd, which was completed in January 2019. ($1 = 106.0300 yen) #manchesterunited#manchestercity#HealthForAll#HealthBroadcastingService#tampabaybuccaneers#Covid-19#nba#brooklynnets #sacramentokings#losangeleslakers#HealthBroadcastingServiceInPublicHealthPartnership#kimkardashian#cdguadalajara#liverpoolfc#sanjosesharks#deutscherwetterdienst#wellsfargo#woodyallen#ginacarano#theherdwithcolin#sacramentokings#lasvegasraiders#sanantoniospurs#atleticomadrid#chesterfieldfc#birdsofafeatherpaulinequirke#vegasgoldenknights#smartmotorway#purim#charlottehornets#liverpoolfc#brooklynnets#momentswithannie #losangeleslakers #sanantoniospurs#gonzagabulldogs #ladygaga#losangelesclippers#milwaukeebucks#googleboxhttps://www.reuters.com/…/us-takeda-diabetes-sale…
